Clinical Trial: TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07190300) titled 'TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)' on Sept. 16.

Brief Summary: The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

Study Start Date: Nov. 03

Study Type: INTERVENTIONAL

Condition: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Intervention: DRUG: Tulmimetostat...